ETTX News and Press, Entasis Therapeutics Holdings Inc. From 08/05/20

WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Offi...

Gainers:  InnerWorkings (NASDAQ: INWK ) +117% . More news on: InnerWorkings, Inc., Heat Biologics, Inc., Boxlight Corporation, Stocks on the move, , Read more ...

The National Institutes of Health (NIH) has awarded Entasis Therapeutics Holdings' (NASDAQ: ETTX ), an initial contract of ~$3M, with the potential to increase up to $15.5M, to be used for developing novel molecules from its non-β-lactam inhibitor (NBP) platform with expanded antimi...

WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced it has entered into a contract with the National Institut...

The following slide deck was published by Entasis Therapeutics Holdings Inc. in conjunction with this Read more ...

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Offi...

WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranc...

Entasis Therapeutics (NASDAQ: ETTX ): Q1 GAAP EPS of -$1.15 misses by $0.15 . More news on: Entasis Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a bu...

WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the init...